All Posts

Summary: Many exciting prostate cancer catalysts are coming throughout the year See the table below for some upcoming catalysts and sign...

Summary: ESPR first announced Clear Outcomes Nexletol data in Dec 2022, but only stated the primary endpoint was met They reported that...

Originally posted 2/6/2023; last updated 5/5/2023 Summary: Many exciting breast cancer catalysts are coming throughout the year See the...

Already a month into 2023 but still a lot of big events coming this quarter. We have a number of readouts coming including GTHX phase 3...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Originally published 2/3/23; last updated 3/29/23 Summary: Many exciting liver disease catalysts are coming in the first quarter of the...

Summary: The CYTK PDUFA for Omecamtiv Mecarbil is coming up on February 28 for heart failure with reduced ejection fraction (HErEF) The...

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3...

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...